Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Latin American Cooperative Oncology Group | OTHER |
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bevacizumab | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
| |
| Trastuzumab | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
| |
| Ado-trastuzumab emtamsine | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
| |
| Pertuzumab | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
| |
| Atezolizumab | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bevacizumab | Drug | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Different Breast Cancer Subtypes at Diagnosis in Latin America | Baseline up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Pathological Complete Response (pCR defined ypT0/is, N0) | Baseline up to approximately 6 years | |
| Percentage of Participants with Locoregional Recurrence (LRR) | Baseline up to approximately 6 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The patients will be recruited from approximately 10 countries and from a variety of healthcare sites (ex: specialty care, private practice, teaching institution, etc.)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Alexander Fleming | Buenos Aires | 1426 | Argentina | |||
| Instituto Oncologico De Cordoba |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Capecitabine | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
|
|
| Trastuzumab | Drug | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
|
|
| Ado-trastuzumab emtamsine | Drug | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
|
|
| Pertuzumab | Drug | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
|
|
| Atezolizumab | Drug | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
|
|
| Capecitabine | Drug | Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling. |
|
| Percentage of Participants with Event Free Survival (EFS) | Baseline up to approximately 6 years |
| Percentage of Participants with Invasive Disease-Free Survival (iDFS) | Baseline up to approximately 6 years |
| Percentage of Participants with Overall Survival | Baseline up to approximately 6 years |
| Percentage of Participants with Objective Response Rate (ORR) | Baseline up to approximately 6 years |
| Percentage of Participants with Anti-Cancer Treatment Modifications | Baseline up to approximately 6 years |
| Percentage of Participants with Breast Cancer Treatment based on Different Socio-Demographics Characteristics | Baseline up to approximately 6 years |
| Percentage of Participants (During Observation Period) with Pregnancy | Baseline up to approximately 6 years |
| Percentage of Participants (during Observation Period) with Pregnancy Outcomes | Baseline up to approximately 6 years |
| Percentage of Participants with Non-Serious Adverse Events of Special Interests | Baseline up to approximately 6 years |
| Percentage of Participants with AEs Leading to Discontinuation or Dose Modification | Baseline up to approximately 6 years |
| Percentage of Participants with Cardiac Safety Events | Baseline up to approximately 6 years |
| Percentage of Participants Adherent to Predefined Clinical Guideliens Regarding Anti-Cancer Treatment Regimens | Baseline up to approximately 6 years |
| Percentage of Partcipants with Access to Biomarker Testing and Diagnostic Methods | Baseline up to approximately 6 years |
| Córdoba |
| 5000 |
| Argentina |
| Hospital Privado Centro Medico de Cordoba | Córdoba | 5016 | Argentina |
| Hospital de Morón | Morón | Argentina |
| Instituto de Oncología de Rosario | Rosario | S2000KZE | Argentina |
| Sanatorio de la Mujer | Rosario | S2000ORE | Argentina |
| Crio - Centro Regional Integrado de Oncologia | Fortaleza | Ceará | 60336-550 | Brazil |
| Hospital do Câncer de Londrina | Londrina | Paraná | 86015-520 | Brazil |
| Hospital Jardim Amália | Volta Redonda | Rio de Janeiro | 27251-260 | Brazil |
| Inst. de Vita | Caxias do Sul | Rio Grande do Sul | 95020-450 | Brazil |
| Centro de Pesquisa em Oncologia | Porto Alegre | Rio Grande do Sul | 90840-440 | Brazil |
| Instituto Nacional de Cancer - INCa | Rio de Janeiro | 20560-120 | Brazil |
| Instituto Brasileiro De Controle Do Câncer - IBCC | São Paulo | 03102-002 | Brazil |
| Clinica Las Condes | Santiago | 7591046 | Chile |
| Instituto Nacional del Cancer | Santiago | 8380000 | Chile |
| Hospital Dr. Hernan Henriquez Aravena | Temuco | 4781151 | Chile |
| Organización Clínica Bonnadona Prevenir S.A.S | Barranquilla | Colombia |
| Inst. Nacional de Cancerologia | Bogotá | Colombia |
| Centro Medico Imbanaco | Cali | Colombia |
| Fundacion Cardiovascular de Colombia - Instituto del Corazón | Floridablanca | Colombia |
| Hospital Hermanos Ameijeiras | La Habana | 10300 | Cuba |
| Instituto de Oncologia Dr. Heriberto Pieter | Santo Domingo | 10150 | Dominican Republic |
| Grupo Angeles | Guatemala City | 01015 | Guatemala |
| Instituto Nacional de Cancerologia | Mexico City | Mexico CITY (federal District) | 14080 | Mexico |
| Hospital Zambrano Hellion TecSalud | Monterrey | Nuevo León | Mexico |
| Centro Oncologico Estatal ISSEMYM | Toluca | 50180 | Mexico |
| Instituto Nacional de Enfermedades Neoplasicas | Lima | 15038 | Peru |
| Clinica Internacional, Sede San Borja | Lima | Lima 41 | Peru |
| Aliada Centro Oncologico | Lima | Peru |
| Sanatorio CASMU | Montevideo | Uruguay |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| D000068878 | Trastuzumab |
| D000080044 | Ado-Trastuzumab Emtansine |
| C485206 | pertuzumab |
| C000594389 | atezolizumab |
| D000069287 | Capecitabine |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D008453 | Maytansine |
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D047029 | Lactams, Macrocyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D005472 | Fluorouracil |
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
Not provided
Not provided